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Despite the rarity of the condition, 
the study of patients with ichthyosis 
has had a substantial impact in two 
areas: (i) fundamental discoveries 
about critical skin functions and (ii) 
development of treatments that also 
benefit patients with more common 
skin diseases. It is not unreasonable to 
anticipate that stimulation of research 
in ichthyosis will continue to impact 
the skin disease community in this 
fashion.
The meeting was organized into 
five sessions with a mixture of formal 
presentations and lively discussion.
Frontiers in genetic diagnosis
The identification of genes that cause 
ichthyosis has fundamentally changed 
the way we think about this group 
of diseases and about skin biology. 
Judith Fischer (Centre National de 
Genotypage, Evry, France) gave a com-
prehensive review of how positional 
cloning has been used in the past 
20 years to identify disease-causing 
genes. She described how her group 
used 130 consanguineous families to 
identify seven new genes that cause 
autosomal recessive congenital ich-
thyosis (ARCI). When 500 additional 
ARCI patients were screened for those 
genes plus transglutaminase 1, 22% 
still had no identifiable mutations. She 
indicated that single-nucleotide poly-
morphism arrays and whole-exome 
sequencing will speed mutant gene 
identification and reduce cost. Eli 
Sprecher (Sourasky Medical Center, 
Tel Aviv, Israel) spoke about the iden-
tification of genes causing syndro-
mic ichthyoses—CEDNIK (cerebral 
Frontiers in Ichthyosis Research, an 
international meeting of investigators 
actively involved in research directly 
related to ichthyosis, was held in June 
2010, immediately preceded the bian-
nual family conference held by the 
Foundation for Ichthyosis and Related 
Skin Types, Inc. (FIRST), an ichthyo-
sis patient-support organization.* The 
meeting was designed to foster col-
laboration among investigators and 
between patients and investigators. It 
was an opportunity for the most deep-
ly engaged individuals to begin a dia-
logue about efficient and effective ways 
to utilize scarce resources to advance 
research in ichthyosis. Invited speakers 
were asked to present ongoing research 
and their perspectives on significant 
challenges and opportunities (Figure 1).
Leonard Milstone (Yale University, 
New Haven, CT, USA) introduced the 
meeting, noting that it was held on the 
tenth anniversary of the announced 
completion of the Human Genome 
Project. The identification of genes 
associated with human disease was 
an important spin-off from that world-
wide effort and the ichthyoses were 
no exception. In the past 20 years we 
have come to recognize that the ich-
thyosis phenotype can be attributed 
to an unexpectedly large number of 
genes, whose coded proteins have a 
broad array of functions. This new per-
spective demonstrates that no aspect 
of epidermal biology can be taken for 
granted. This new appreciation opens 
the door for renewed collaboration 
between basic scientists interested in 
epidermal biology and keratinization 
and those interested in ichthyosis.
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dysgenesis, neuropathy, ichthyosis, 
and keratoderma caused by mutation 
in SNAP29) and ANE (alopecia, neu-
rologic defect, and endocrinopathies 
caused by mutation in RBM28). He 
indicated that “rare is common” when 
looking for new disease genes in geo-
graphically, ethnically, or politically 
isolated populations and suggested 
that this approach will continue to be 
important in identifying proteins with 
critical functions in epidermis.
Keith Choate (Yale University) 
reported on a group of patients with 
ichthyosis for whom he and Leonard 
Milstone collected data; the key ques-
tions for this group was not what 
caused the ichthyosis but what caused 
the areas of normal-appearing skin. 
He demonstrated that the normal 
skin resulted from frequent, unique, 
somatic recombination events in kera-
tinocytes and indicated how those 
independent somatic cell events were 
used to localize and identify the gene 
for ichthyosis with confetti. Amy Paller 
(Northwestern University, Chicago, IL, 
USA) concluded with a provocative 
review of the pros and cons of giving 
all patients with ichthyosis a genetic 
diagnosis. She noted that genetic 
diagnosis will change the way we 
think about classification, pathogene-
sis, prognosis, and therapy. Currently, 
the cost for making genetic diagnosis 
widely available in the United States 
is prohibitive.
Frontiers in understanding pathogenesis
As important and satisfying as it has 
been to learn about the genes and 
proteins associated with ichthyosis, 
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we are still quite ignorant, in many 
cases, about normal protein functions 
or what precisely goes wrong in a cell 
with a mutant protein. William Rizzo 
(University of Nebraska, Omaha, NE, 
USA) gave a critical overview of lipid 
synthetic pathways in epidermis. For 
each enzyme defect known to be asso-
ciated with ichthyosis, he revealed our 
inability to explain adequately all the 
clinical manifestations or to under-
stand whether pathogenesis moved 
through substrate accumulation or 
product deficiency. In the mouse 
model of Sjögren–Larsson syndrome 
that he created, he unexpectedly iden-
tified enzyme redundancy in mice but 
not in humans. Equally unexpected 
was the observation that the deleted 
gene resulted in substantially differ-
ent phenotypes depending on the 
mouse strain—providing an oppor-
tunity to identify disease-modifying 
genes. Mason Freeman and Michael 
Fitzgerald (Harvard University, Boston, 
MA, USA) have created mouse models 
of mutant ATP-binding cassette A3 and 
A12 (ABCA3 and ABCA12). Fitzgerald 
explained the ways in which these 
mouse models of deficiencies in relat-
ed lipid transporters differ from each 
other and how they have been useful 
in understanding the respective human 
deficiencies—neonatal respiratory 
distress syndrome and Harlequin ich-
thyosis—but also why they have been 
disappointing in elucidating disease 
pathogenesis completely. He suggest-
ed that mass spectroscopic analysis of 
lipids in this and similar monogenic 
epidermal diseases could lead to new 
therapeutic strategies.
Peter Elias (University of California, 
San Francisco, CA, USA) noted that 
ichthyosis therapy had often simply 
focused on scale removal. He urged 
the audience to consider pathogenesis-
based therapy for ichthyotic epidermis 
caused by defects in lipid synthesis 
and delivery pathways. Such an 
approach might employ both pathway 
inhibitors to reduce toxic lipid metab-
olites and lipid replacement to restore 
deficient products. Hiroshi Shimizu 
(Hokkaido University, Sapporo, Japan) 
spoke about his experience with skin 
cancer occurring in unusual anatomic 
locations in patients with ichthyosis. 
He noted that increased risk for 
skin cancer is accepted in Kindler 
syndrome, xeroderma pigmentosum, 
and recessive dystrophic epiderm-
olysis bullosa, but that there are only 
a few anecdotal reports of cancer in 
ichthyosis. In general, we know little 
about the natural history of patients 
with ichthyosis, their relative lifetime 
risk for cancer or, if the risk is greater 
than normal, how the mutant gene 
might increase risk.
Alain Hovnanian (University of 
Paris, France) spoke about multiple 
effects of mutations in the gene for the 
serine protease inhibitor, Kazal-type 
5 (SPINK5), the cause of Netherton 
syndrome. The protein product of 
SPINK5—lymphoepithelial Kazal-type 
5, or LEKTI—inhibits protease activ-
ity in the epidermis, and he described 
molecular pathways by which LEKTI 
deficiency could lead to allergy 
and inflammation, as well as to its 
more obvious role in desquamation. 
Identifying the specific enzyme(s) 
inhibited by LEKTI could lead to 
development of small-molecule 
enzyme inhibitors, an area of active 
research in his lab. Pierre Coulombe 
(Johns Hopkins University, Baltimore, 
MD, USA) reviewed the well-accepted 
structural function of keratins in resist-
ing shear stress and then provided less 
well-appreciated examples of keratin’s 
roles in signaling activity. As examples 
he mentioned the roles of K5 and K14 
in pigment transfer from melanocytes 
to keratinocytes and of K17 in modu-
lating patched pathway-mediated 
tumorigenesis and in Th1/Th2 immune 
balance in epidermis.
Frontiers in shared reagents and resources
Investigative communities are depen-
dent on widely accepted tools, valid 
measures of events, and outcomes 
that interest them. Few such tools 
exist or have been widely applied to 
research in ichthyosis. If translational 
research in ichthyosis is to move for-
ward, such tools must be devised and 
validated. Mary Williams (University 
of California, San Francisco) intro-
duced this session by noting the 
major issues faced by those with 
ichthyosis: impaired barrier function 
and increased scale. She reviewed 
and critiqued the various physi-
cal and chemical methods currently 
employed to assess these issues. She 
described capabilities of additional 
physical measurements, such as ultra-
sound, confocal microscopy, Raman 
spectro scopy, and optical coherence 
tomography, which have yet to be 
applied to ichthyosis. Transepidermal 
water loss, hydration, and pH are 
measurements commonly employed 
in clinical and laboratory studies, 
but they have not been widely used 
in patients with well-characterized 
ichthyosis.
Roger Kaspar (Transderm, Inc., 
Santa Cruz, CA, USA) spoke about his 
recent experience developing a small 
interfering RNA (siRNA) to treat pachy-
onychia congenita. Severe pain upon 
intralesional delivery of the siRNA 
to a single patient precluded its con-
tinued use in that manner. However, 
that problematic experience spawned 
a collaborative effort to develop rel-
evant, reproducible, widely avail-
able test systems to identify and opti-
mize “patient-friendly” delivery of 
therapeutic nucleic acids to human 
epidermis. Dr. Kaspar acknowledged 
the key role played by the patient sup-
port group, PC Project, in pushing the 
clinical trial forward and promoting 
a collaborative atmosphere. Robert 
Rice (University of California, Davis, 
CA, USA) posited that the cornified 
envelope could be viewed as a snap-
shot of the health of the upper layer of 
epidermis at the time it is formed and 
that different diseases of epidermis 
might have distinct peptide signatures 
retained in the cornified envelope. 
He showed preliminary mass spec-
troscopic data demonstrating repro-
ducibility of peptide signatures from 
cornified envelopes collected from 
normal skin, and he showed some dif-
ferences in envelopes collected from 
patients with ichthyosis, emphasizing 
that further work is needed to under-
stand the significance of the findings.
Dennis Roop (University of 
Colorado, Aurora, CO, USA) spoke 
about the promise and practicality 
of using a patient’s keratinocytes to 
produce induced pluripotent stem 
(iPS) cells that might be used to treat 
genetic skin disease. He described his 
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recent success in generating iPS cells 
from a patient with epidermolytic 
ichthyosis, which was supported by a 
grant from FIRST. He then explained 
that his future goal was to correct 
the genetic defect in these iPS cells 
and then differentiate them back into 
keratinocytes that could ultimately be 
returned to the patient as an autograft. 
A frank discussion of obstacles imped-
ing translation of this technology into 
patient treatment ensued. Seuphy 
Chen (Emory University, Atlanta, GA, 
USA) presented recent work creating 
and validating an ichthyosis clini-
cal severity index for several types of 
ichthyosis. She indicated that some of 
the measures that clinicians have used 
routinely to rate severity of ichthyo-
sis are not necessarily the measures 
that ichthyosis patients feel have the 
greatest impact on quality of life, hair 
loss being a specific example. She 
explained how improvements can be 
made in the tool she devised.
Frontiers in preparing for clinical trials
Embarking on a clinical trial is not 
for the faint of heart or thin skinned. 
Few of the investigators or patient 
participants in clinical trials in rare 
diseases are prepared for negotiating 
the complexities of local and nation-
al regulatory agencies, reporting 
and monitoring expectations, and 
fundraising. Heiko Traupe (University 
Hospital, Muenster, Germany) spoke 
about the long journey from molecular 
insights to therapeutic innovation, 
using three examples. First, he out-
lined recommendations for an inter-
nationally consistent classification 
and nomenclature made by last year’s 
ichthyosis consensus conference in 
Soreze, France. Second, he used his 
group’s interest in transglutaminase 
1 mutations and delivery of active 
enzyme to deficient epidermis as an 
example of preclinical challenges that 
are faced by investigators trying to 
develop new approaches to therapy. 
Third, he used the demise of liarozole, 
a new oral agent to treat ichthyosis, 
as an example of how great effort and 
some promise can be extinguished by 
business, not medical decisions.
Sancy Leachman (University of 
Utah, Salt Lake City, UT, USA) briefly 
reviewed her successful clinical trial 
of intralesional allele-specific siRNA 
to reduce hyperkeratosis in the callus 
of pachyonychia congenita. She then 
outlined her views of the critical com-
ponents in the path toward a success-
ful clinical trial. Because such trials 
in rare disease usually include repre-
sentatives of academia, industry, and 
patient advocate groups, she empha-
sized that each needed to understand 
how the others operate. Although 
academics are often creative, expert in 
the area, and adhere to scientific rigor, 
they also can be slow-moving, bureau-
cratic, and independent (noncollegial). 
Industry is goal oriented, outcome 
driven, and flexible—but can lack 
informational depth and have a strong 
financial bias. Patient advocacy groups 
bring a sense of urgency, financial sup-
port, and effective advocacy; however, 
they often need education in scientific 
rigor and the complexities of drug 
development, they can lack focus, 
and they are relatively more suscep-
tible to whims of personal bias. Philip 
Fleckman (University of Washington, 
Seattle, USA) reviewed the design 
and accomplishments of the existing 
Ichthyosis Registry that was supported 
for 10 years by the National Institutes 
of Health (NIH), but has not enrolled 
new patients in the past 6 years since 
NIH funding terminated. He then pre-
sented his goals for a new registry and 
raised the issues of who might support 
it, who would “own” the data, and 
potential rules for data sharing.
Frontiers in physician–scientist–patient 
collaboration
This session brought together research 
investigators with “Ambassadors” identi-
fied by FIRST—individuals affected by a 
specific type of ichthyosis or their par-
ents. Six small groups representing 
specific genotypes and a group 
representing those who remain 
“undiagnosed” met separately, reflect-
ing the belief that progress in research 
would increasingly require a focus 
on specific genotypes. Each group 
was asked to identify short- and long-
term research objectives and ways in 
which the different constituencies—
basic scientists, clinical investigators 
and patients—could help each other. 
Virtually all supported the idea that 
future research should focus on specif-
ic genotypes. Other recurrent themes 
included (i) access to genetic diagno-
sis at a reasonable cost, (ii) an active 
patient registry, (iii) more clinical 
information about natural histories of 
each type of ichthyosis and long-term 
outcomes, (iv) support for centers of 
research and clinical excellence in ich-
thyosis, and (v) one recurring clinical 
concern: itch and how to treat it.
Figure 1. Attendees at the Frontiers in ichthyosis research meeting, June 2010.
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In the final open discussion, there 
was enthusiasm for convening meetings 
of this kind in the future, possibly in dif-
ferent countries. Two working groups 
were established. One group will 
explore the feasibility and parameters 
of a collaborative inter national effort 
to establish a registry of patients with 
ichthyosis. The second will consider 
practical and efficient ways to provide 
genetic diagnoses to patients with ich-
thyosis. It was recognized that vigorous 
advocacy by patient support groups 
in many countries might be necessary 
to generate requisite governmental, 
insurance-industry, or private support 
to make genetic diagnosis widely 
available. There was broad agreement 
that standardized, clinical evaluation 
tools would be highly desirable for 
future investigations into the natural 
history or response to therapy for each 
type of ichthyosis. It was suggested 
that patient support groups could 
assist in the development of visual 
analog, validated, widely available, 
genotype-specific clinical severity 
scales. Finally, it was recognized 
that in the face of scarce resources—
limited numbers of patients, limited 
numbers of knowledgeable clinicians, 
limited numbers of preclinical 
scientists working on ichthyosis, and 
limited funding—progress in translat-
ing new approaches to therapy might 
likely require agreement to establish 
and coordinate centers of research/
translation excellence.
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